Abstracts tagged "scleroderma and systemic lupus erythematosus (SLE)"

Abstract Number: 1957 • 2017 ACR/ARHP Annual Meeting
Impact of Maternal Systemic Autoimmune Rheumatic Diseases on Neonatal Outcomes: A Population-Level Analysis
Stephanie Keeling¹, Anamaria Savu² and Padmaja Kaul³, ¹Department of Medicine, University of Alberta, Division of Rheumatology, Edmonton, AB, Canada, ²Canadian Vigour Center, Edmonton, AB, Canada, ³Cardiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The impact of systemic autoimmune rheumatic diseases (SARDS) on peripartum outcomes is not well described at a population level despite the potential for active…
Abstract Number: 2091 • 2014 ACR/ARHP Annual Meeting
Plasma Microparticle Protein Features Distinctively Classify Systemic Lupus Erythematosus and Systemic Sclerosis and Their Clinical Phenotype
Ole Østergaard¹, Christoffer T. Nielsen², Line V. Iversen³, Anders A. Bengtsson⁴, Søren Jacobsen⁵ and Niels H. H. Heegaard⁶, ¹Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institute, Copenhagen S, Denmark, ²Infectious Diseases and Rheumatology, University Hospital Rigshospitalet, Copenhagen, Denmark, ³Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, ⁴Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ⁵Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁶Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense C, Denmark
Background/Purpose Plasma microparticles (MPs) comprise a heterogenous population of submicron membraneous vesicles shed from the cell-surface both constitutively and as a consequence of pathological processes.…
Abstract Number: 2015 • 2014 ACR/ARHP Annual Meeting
Fine Particulate Air Pollution and Systemic Autoimmune Rheumatic Disease in Two Canadian Provinces
Sasha Bernatsky¹, Audrey Smargiassi², Cheryl Barnabe³, Lawrence W. Svenson⁴, Allan Brand⁵, Marie Hudson⁶, Steven M. Edworthy⁷, Ann E. Clarke³, Paul R. Fortin⁸, Patrick Belisle⁹ and Lawrence Joseph¹⁰, ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Département de santé environnementale et santé au travail, Université de Montréal, Montréal, QC, Canada, ³Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁴Community Health Sciences, University of Calgary, Calgary, AB, Canada, ⁵Institut national de santé publique du Québec, Montreal, QC, Canada, ⁶Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁷The University of Calgary, Calgary, AB, Canada, ⁸Rheumatology, Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, Canada, ⁹Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada
Background/Purpose: To estimate the degree to which fine particulate (PM2.5) air pollution is associated with systemic autoimmune rheumatic diseases (SARDs). Methods: We used population-based administrative…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].